Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Viking Therapeutics is expected to lead this group with its dual GLP-1RA/gastric inhibitory polypeptide receptor (GIP-R) agonist, VK-2735, which is in Phase II for obesity with an oral route of ...

August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the ...

and gastric inhibitory polypeptide drugs as of Wednesday, Jan. 1. The drugs can be used to prevent diabetes and to treat insulin resistance, metabolic syndrome or morbid obesity, according to a ...

Tirzepatide is one of a growing number of popular weight loss drugs that mimic the hormones GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) to manage blood sugar levels ...

As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...

Background Spasmolytic polypeptide-expressing metaplasia (SPEM) is present in more than 90% of resected gastric cancer tissues. However, although widely regarded as a pre-cancerous tissue, its genetic ...

They act by targeting the incretin hormones-glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/Gastric inhibitory polypeptide receptor (GIP-R). It is ...